Researchers at the University of Cape Town's Institute of Infectious Disease and Molecular Medicine (IDM) have secured a pivotal role in a landmark £4.5 million (approximately R100 million) grant from the Wellcome Trust to tackle emerging fungal pathogens, including Emergomyces africanus, a deadly fungus first identified in South Africa. This funding supports the Mycology Bioimaging Initiative (MBI), an international collaboration aimed at revolutionizing how scientists visualize and understand these microscopic threats that claim millions of lives globally each year. For South African higher education, this development underscores UCT's leadership in infectious disease research, fostering advanced training and international partnerships that promise to elevate local expertise in medical mycology.

The initiative comes at a critical time, as fungal infections disproportionately burden low- and middle-income countries like South Africa, where high HIV prevalence exacerbates vulnerability. With fungal diseases responsible for over 2.5 million deaths annually worldwide—affecting 6.5 million people—and contributing significantly to AIDS-related mortality, innovations in diagnostics and treatments are urgently needed. UCT IDM's involvement positions the institution as a hub for cutting-edge bioimaging research, potentially accelerating breakthroughs in pathogen detection and management.

Understanding Emergomyces africanus: South Africa's Emerging Fungal Nemesis

Emergomyces africanus, a thermally dimorphic fungus—meaning it switches from mold-like in soil to yeast-like in the body—was first described in South Africa in 2013. Endemic to southern Africa, it thrives in soil and disseminates via inhalation, primarily targeting immunocompromised individuals, especially those with advanced HIV (CD4 counts below 100 cells/μL). Symptoms start with skin lesions but rapidly progress to systemic infection involving lungs, dissemination, and high mortality—around 50% case fatality rate (CFR) even with treatment.

In South Africa, emergomycosis has surged as the most common dimorphic fungal infection diagnosed in HIV patients. While exact case numbers are underreported due to diagnostic challenges, prospective studies in the Western Cape identified it in 15% of HIV patients with skin lesions and low CD4 counts. PCR detection in 30% of Cape Town soil samples confirms environmental presence. Unlike Cryptococcus, which dominates headlines, Emergomyces mimics other diseases, delaying diagnosis and worsening outcomes.

• First reported cases: 52 patients in SA, 2013-2015, all HIV+.
• Global spread: Now reported in Americas, Asia, Europe, but Africa bears the brunt.
• Treatment: Amphotericin B and itraconazole, but resistance emerging; poor access in rural areas.

Professor Jennifer Hoving at UCT IDM, leading the Emergomyces focus, notes the pathogen's rapid evolution as a public health concern, emphasizing the need for better tools to study its growth and host interaction.

The Broader Burden of Fungal Infections in South Africa

South Africa faces one of the world's highest fungal disease burdens, driven by 7.5 million HIV cases, TB co-infections, and poverty. Annual estimates include 8,357 cryptococcal meningitis cases (leading AIDS killer), 4,452 Pneumocystis pneumonia, 3,885 invasive aspergillosis, and thousands more candidaemia (5,421) and peritonitis (1,901). Chronic pulmonary aspergillosis affects 89,416, allergic bronchopulmonary aspergillosis 60,591. Sub-Saharan Africa sees 50% mortality for invasive fungal infections.

Emerging threats like Emergomyces join WHO's fungal priority pathogens list (high priority), alongside Cryptococcus (critical), Candida auris, Aspergillus fumigatus. In SA, HIV-related fungi cause over 112,000 deaths yearly from cryptococcal meningitis alone. Diagnostic gaps—culture-based tests take weeks—lead to misdiagnosis as TB or bacterial pneumonia. The MBI addresses this by prioritizing Africa-relevant pathogens.

Stakeholder perspectives: Clinicians report increased emergomycosis cases post-2020; patients in townships face delayed care. Government reports highlight AMR rise, complicating itraconazole use.

Unpacking the Mycology Bioimaging Initiative: A Game-Changer

Led by Dr Elizabeth Ballou (Univ Exeter), with Prof Peter Swain (Edinburgh), the MBI spans 6.5 years, developing microfluidics for fungal cell growth observation, fluorescent reporters for subcellular dynamics, AI-driven image analysis, and light-sheet microscopy for brain infections. UCT IDM contributes Africa-specific expertise, establishing bioimaging labs.

Process: Step 1—Sample prep with reporters; Step 2—Microfluidic traps capture growth; Step 3—High-res imaging; Step 4—Computational modeling predicts spread. Outputs: Open-source tools, reducing global R&D costs.

Spotlight on UCT IDM Trailblazers

Prof Jennifer Hoving (IDM, CMM AFRICA Unit) pioneers Emergomyces immunology, authoring key papers on its pathogenesis. Her lab dissects host-fungus interplay in HIV patients.

Assoc Prof Rachael Dangarembizi (Neuroscience Institute/CMM AFRICA) focuses Cryptococcus-induced neurodegeneration, using models to reveal immune-mediated brain damage in IRIS. Recent Trends Neurosci paper highlights midbrain role in pulmonary dysfunction.

Both build on AFGrica Unit (est. 2017, Univ Aberdeen/UCT), training African scientists, achieving diagnostics advances.

Bioimaging Revolution: Tools Transforming Fungal Research

Traditional microscopy misses dynamics; MBI's innovations enable real-time tracking. E.g., light-sheet for 3D Cryptococcus-brain views, revealing filament invasion. Benefits: Faster drug screening, resistance mechanisms ID'd early.

• Microfluidics: Traps single cells for growth assays.
• Fluorescent reporters: Track gene expression live.
• AI pipelines: Analyze petabytes of data.
• Risks: Tech access inequities, data privacy.

Building Capacity: Training Africa's Next Mycologists

MBI prioritizes workshops, exchanges for African labs. Annual events in Cape Town build skills in imaging/analysis. Impacts higher ed: PhD/postdoc opps at UCT, career pipelines in scarce field. SA unis like UCT/Wits lead, but need more funding for retention.WHO Fungal Priority Pathogens List guides priorities.

Real-World Impacts and Case Studies

In Western Cape, 2017 study: 425 HIV patients screened, Emergomyces in 64 (15%). Survival 47% vs 95% non-fungals. MBI tools could cut diagnosis time from weeks to hours. Timeline: 2026 pilots in SA clinics; 2030 global rollout.

Stakeholders: DHIS reports rising fungal lab positives; experts call for national surveillance.

Challenges, Solutions, and Future Outlook

Challenges: AMR (e.g., azole-resistant Emergomyces), climate aiding spread, HIV/TB overlap. Solutions: MBI data informs vaccines/antifungals; policy for fungal inclusion in NTPs.

Future: UCT IDM eyes spin-offs, industry ties. For higher ed, boosts rankings, attracts talent. Actionable: Aspiring researchers apply UCT fellowships; unis invest bioimaging.

Photo by Mauro Lima on Unsplash

Implications for Higher Education and Research Careers in South Africa

This grant elevates UCT's global profile, creating jobs in mycology—scarce amid faculty shortages. Links to research positions. Students gain hands-on training, boosting employability in pharma/biotech. Unis must scale interdisciplinary programs (microbio + imaging + AI).

Outlook: Positions SA as Africa leader, aligning NEP2020 goals for health research.